Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results

PKparameters Subject’s pharmacokinetic’s (PK) parameters from the population distributions defined by the population mean. nPK The length of time points. time The sampling

As two agents can have a synergistic, antagonistic or independent effect on toxicity, the question of achieving doses (for each agent) that nearly approximate

Comme, dans la présente affaire, la valeur litigieuse retenue par la dernière instance cantonale avait été fixée à Fr. 6'000,-, le recours en matière civile au

À l' aide de deux tâches projectives et d'un questionnaire sur la perception des figures parentales, le fonctionnement intrapsychique et l' intériorisation

During that time, I observed and conducted interviews at five locations: the Charles de Gaulle Paediatric Hospital in Ouagadougou, where mothers and their children

In the second case, no finite population size is assumed, but the gain from future patients is geometrically discounted, so that the gain from patient j if they receive treatment i is

Wages, as stated in our paper, we used the POCRM design starting at the lowest dose level, based on current practice in Phase I oncology clinical trial.. The authors

We report here the results for the two groups of children with relapsing or refractory brain tumors included in a multicentre phase II clinical trial using a four-drug